Cargando…

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy

Deregulation of the Phosphoinositide 3-kinase (PI3K)/AKT signalling network is a hallmark of oncogenesis. Also medulloblastoma, the most common malignant brain tumor in children, is characterized by high levels of AKT phosphorylation and activated PI3K signalling in medulloblastoma is associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ehrhardt, Michael, Craveiro, Rogerio B., Holst, Martin I., Pietsch, Torsten, Dilloo, Dagmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4359256/ https://www.ncbi.nlm.nih.gov/pubmed/25596739

Ejemplares similares

The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
por: Ehrhardt, Michael, et al.
Publicado: (2018)

In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy
por: Craveiro, Rogerio B., et al.
Publicado: (2014)

The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition
por: Craveiro, Rogerio B, et al.
Publicado: (2017)

The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro
por: Schoen, Leonie F., et al.
Publicado: (2022)

GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway
por: Chen, Haifeng, et al.
Publicado: (2022)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
por: Usman, Muhammad Waqas, et al.
Publicado: (2018)

The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor
por: Tzeng, Huey-En, et al.
Publicado: (2015)

Author Correction: Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling
por: Usman, Muhammad Waqas, et al.
Publicado: (2019)

(11)C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging
por: Han, Na, et al.
Publicado: (2019)

Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941
por: Mehraj, Umar, et al.
Publicado: (2022)

The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer
por: Wang, Lingfei, et al.
Publicado: (2017)

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics
por: Lu, Tong, et al.
Publicado: (2017)

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
por: Schöffski, Patrick, et al.
Publicado: (2018)

The MEK-ERK-MST1 Axis Potentiates the Activation of the Extrinsic Apoptotic Pathway during GDC-0941 Treatment in Jurkat T Cells
por: Nováková, Jana, et al.
Publicado: (2019)

Inhibition of PI3K Class IA Kinases Using GDC-0941 Overcomes Cytoprotection of Multiple Myeloma Cells in the Osteoclastic Bone Marrow Microenvironment Enhancing the Efficacy of Current Clinical Therapeutics
por: Kikuchi, Hugh, et al.
Publicado: (2023)

Downregulation of 14q32 microRNAs in Primary Human Desmoplastic Medulloblastoma
por: Lucon, Danielle Ribeiro, et al.
Publicado: (2013)

Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR
por: Heffron, Timothy P., et al.
Publicado: (2016)

GDC respond to crisis
Publicado: (2020)

Mentoring, performance and the GDC
por: Saw, Mabel, et al.
Publicado: (2021)

RTK-Dependent Inducible Degradation of Mutant PI3Kα Drives GDC-0077 (Inavolisib) Efficacy
por: Song, Kyung W., et al.
Publicado: (2022)

GDC announces new chair
Publicado: (2021)

Novel Dual PI3K/mTOR Inhibitor, Apitolisib (GDC-0980), Inhibits Growth and Induces Apoptosis in Human Glioblastoma Cells
por: Omeljaniuk, Wioleta Justyna, et al.
Publicado: (2021)

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
por: Jonchere, Barbara, et al.
Publicado: (2023)

Medulloblastoma stem cells: Promising targets in medulloblastoma therapy
por: Huang, Guo‐Hao, et al.
Publicado: (2016)

Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152
por: Tchoghandjian, A, et al.
Publicado: (2016)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
por: Schönberger, Stefan, et al.
Publicado: (2020)

GDC 2: Compression of large collections of genomes
por: Deorowicz, Sebastian, et al.
Publicado: (2015)

GDC publishes 2019 fitness to practise statistics
Publicado: (2020)

GDC statement on complaints during the pandemic welcomed
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

GDC calls for DCPs to check CPD records
Publicado: (2022)

Brentuximab vedotin exerts profound antiproliferative and pro‐apoptotic efficacy in CD30‐positive as well as cocultured CD30‐negative germ cell tumour cell lines
por: Schönberger, Stefan, et al.
Publicado: (2017)

Update on the integrated histopathological and genetic classification of medulloblastoma – a practical diagnostic guideline
por: Pietsch, Torsten, et al.
Publicado: (2016)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

GDC and CQC issue statement on life-support training
Publicado: (2020)

GDC highlights importance of clear public safety COVID information
Publicado: (2020)

Inhibition of PI3K Signalling Selectively Affects Medulloblastoma Cancer Stem Cells
por: Frasson, Chiara, et al.
Publicado: (2015)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
por: Meininger, Gary E., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_963a914dunuqc7be4ih43cflni